logo
  Join        Login             Stock Quote

Marshall Edwards (MSHL) Gets New Patent For Cancer Treating Drug

 April 25, 2012 10:48 AM
 


(By Balaseshan S) Marshall Edwards Inc. (NASDAQ:MSHL), a development-stage oncology company, said it received a new patent for its lead drug candidate ME-143 for use in treating cancer.

The key U.S. patent for ME-143 follows on the heels of a related patent for ME-344 as well as a composition patent for both compounds, solidifying the intellectual property position surrounding the company's two lead oncology drug candidates.

The U.S. Patent and Trademark Office has issued Patent No. 8,163,795, which is expected to provide protection until September 2025, covering the company's lead drug candidate ME-143.

[Related -Marshall Edwards (MSHL) Gets FDA Approval Of IND Application For Cancer Test]

The company also said it has received notices of allowance from the Japanese Patent Office for two patents that cover the ME-143 and ME-344 compositions of matter, respectively, and their use in treating cancer.

The company's lead drug candidates, ME-143 and ME-344, have been shown in laboratory studies to interact with specific enzyme targets resulting in inhibition of tumor cell metabolism, a function critical for cancer cell survival.

Marshall Edwards initiated a Phase 1 clinical trial of intravenous ME-143 in patients with solid refractory tumors in September 2011 and plans to present safety and pharmacokinetic data from the trial at the American Society of Clinical Oncology Annual Meeting in June 2012.

The company received approval of its Investigational New Drug application for ME-344 in April 2012 and is initiating a Phase 1 clinical trial of intravenous ME-344 in patients with solid refractory tumors.

[Related -Marshall Edwards (MSHL) To Raise $2M Via Private Offering]

Marshall Edwards owns exclusive worldwide rights to all of its drug candidates, including ME-143 and ME-344. The company's intellectual property portfolio now includes 15 issued U.S. patents, at least 12 additional U.S. patent applications, and more than 70 issued foreign patents and 50 foreign patent applications.

MSHL is trading up 1.58% at $0.670 on Wednesday. The stock has been trading between $0.64 and $3.28 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageChart Says This Retailer's Comeback Isn't Finished

One of the surprises, at least on the surface, of the market's recent swoon was the outperformance of read on...

article imageETF Performance Review: Major Asset Classes | 19 Dec 2014

It’s all about real estate investment trusts (REITs) these days when it comes to bullish performance among read on...

article imageOil and Global Stock Markets Rebounding Sharply

So far so good on our expectation of a 4 to 5% pullback and then a resumption of the bull read on...

article imageGrading the FOMC

Love its members or loathe them, you have to admire the gradual impact the policy-making committee has had read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.